Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Overview 7 Therapeutics Development 8 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Products under Development by Stage of Development 8 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Products under Development by Therapy Area 9 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Products under Development by Indication 10 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Products under Development by Companies 13 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Products under Development by Universities/Institutes 15 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Route of Administration 18 Assessment by Molecule Type 19 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Companies Involved in Therapeutics Development 21 Advaxis, Inc. 21 Akshaya Bio Inc. 22 Celgene Corporation 23 Etubics Corporation 24 OSE Immunotherapeutics 25 Vaxon Biotech 26 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Drug Profiles 27 ETBX-011 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 GI-6207 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 OSE-2101 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Peptides to Activate CEACAM5 for Crohn's Disease - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Vaccine to Target CEA for Oncology - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Vaccine to Target CEA for Ovarian Cancer - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Vbx-016 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Vbx-026 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Dormant Projects 41 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Discontinued Products 42 Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Featured News & Press Releases 43 Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer 43 Feb 04, 2016: OSE Pharma Announces U.S. Initiation of Atalante 1, the Company’s Global, Pivotal Phase 3 Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer 43 Jan 06, 2016: OSE Pharma Announces Initiation of Its Pivotal Phase 3 Trial of Tedopi in Non-Small Cell Lung Cancer 44 Sep 29, 2015: OSE Pharma to participate to the Large & Midcap Event in Paris on October 7-8, 2015 45 Aug 05, 2015: Etubics Platform Shown to Significantly Increase Survival Of End Stage Colorectal Cancer Patients 45 Jun 22, 2015: Vaxon Biotech granted Japanese patent for new cancer vaccine candidates 46 May 28, 2015: OSE Pharma and Simbec-­Orion to participate in the 51st annual Meeting of the American Society of Clinical Oncology, May 29th to June 2nd 2015, Chicago 47 Jan 29, 2015: OSE Pharma appoints Simbec-Orion to conduct its Tedopi Phase III international clinical trial in advanced lung cancer patients 47 Sep 15, 2014: Texopi, a new ray of hope for lung cancer immunotherapy 48 Jun 23, 2014: Agreement on Phase 3 Trial Protocol of OSE Pharma's OSE-2101 From the FDA and EMA 49 May 28, 2014: Etubics Will Present Results of Its Colorectal Cancer Phase 1 and 2 Immunotherapy Trial at the Annual American Society of Clinical Oncology Meeting in Chicago 50 Jun 04, 2013: OSE Pharma Announces A Grant From OSEO For Its Targeted Cancer Immune Therapy In Phase III 50 May 06, 2013: Etubics Platform Generates Solid Immune Response In Colorectal Cancer Patients 51 Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer 52 Feb 14, 2013: OSE Pharma Announces The Orphan Drug Status Granted In The US For OSE 2101 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54

List of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by Advaxis, Inc., H1 2016 21 Pipeline by Akshaya Bio Inc., H1 2016 22 Pipeline by Celgene Corporation, H1 2016 23 Pipeline by Etubics Corporation, H1 2016 24 Pipeline by OSE Immunotherapeutics, H1 2016 25 Pipeline by Vaxon Biotech, H1 2016 26 Dormant Projects, H1 2016 41 Discontinued Products, H1 2016 42 List of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Routes of Administration, H1 2016 18 Number of Products by Molecule Types, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 19

Advaxis, Inc. Akshaya Bio Inc. Celgene Corporation Etubics Corporation OSE Immunotherapeutics Vaxon Biotech